News | April 07, 2022
Indian pharma growth likely to moderate in FY23: ICRA
Headwinds related to pricing pressures and rising raw material costs will result in some contraction in margins in Q4 FY22 and FY23
Headwinds related to pricing pressures and rising raw material costs will result in some contraction in margins in Q4 FY22 and FY23
The tentatively approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Pradaxa Capsules of Boehringer lngelheim
An integrated and agile approach enables the pharmaceutical CDMO industry to simplify manufacturing as it moves from primary care medicines to specialty medicines
Global event to kick off as the post-covid era begins in earnest, with theme "beyond the pandemic, into a next wave"
The acquisition will strengthen Lupin’s India formulation business by adding a fast-growing portfolio of vitamins, minerals, supplements and neurological products
Immunocin, an Immuno-modulator drug, significantly reduced the risk of death in the Phase 3 clinical trial in adult patients with moderate-to-severe Covid-19
MilliporeSigma to become the first company to offer a fully integrated ecosystem for advanced process technologies
The aim is to pursue methylation-based tools to better understand biological reactions to pharmaceuticals
GE Healthcare and Elekta aim to meet the major need for radiotherapy solutions across both developed and developing markets
Iktos and Teijin Pharma will collaborate in developing new AI technology aiming to bring further improvement and speed to the drug design process
Subscribe To Our Newsletter & Stay Updated
